Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model

Abstract

Hyperlipidemia is often associated with obesity and diabetes, and can lead to serious complications like atherosclerosis and fatty liver disease. Coagonist of GLP-1 and glucagon receptors is a therapy under clinical investigation for treatment of obesity and diabetes. In this study, we have characterized the mechanism of hypolipidemic effect of a balanced coagonist using high cholesterol-fed hamsters. Tyloxapol-induced hypertriglyceridemia, lipolysis in adipose tissue, and bile homeostasis were assessed after repeated dose treatment of the coagonist of GLP-1 and glucagon receptors (Aib2 C24 chimera 2, SC). Antagonists of GLP-1, glucagon, and FGF21 receptors were coadministered, and FGF21 sensitivity was determined in liver and adipose tissue. Repeated dose treatment of coagonist reduced cholesterol and increased FGF21 in blood and liver. Coagonist treatment reduced hepatic triglyceride secretion, increased lipolysis and reduced body weight. Antagonism of GLP-1 and glucagon receptors partially blocked the effect of the coagonist on lipid metabolism in circulation and liver, while FGF21 receptor antagonist completely abolished it. Glucagon and GLP-1 receptors antagonists blocked the action of coagonist on cholesterol excretion and bile flow in liver, but FGF21 antagonist was not effective. Treatment with the coagonist increased expression of FGF21, FGF21R and cofactor ßKlotho in liver and adipose. In conclusion, coagonist of GLP-1 and glucagon receptors improved lipid metabolism in liver of dyslipidemic hamsters. This effect is partially mediated by GLP-1 and glucagon receptors, and the improved FGF21 sensitivity could be the mechanism of hypolipidemic action of the coagonist of GLP-1/glucagon receptors.

Key words

insulin/glucagons - lipid-lowering drugs - drug research

• References

• 1 Verges B. Pathophysiology of diabetic dyslipidaemia: where are we?. Diabetologia 2015; 58: 886-899
• 2 Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2012; 32: 2104-2112
• 3 Day JW, Gelfanov V, Smiley D. et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers 2012; 98: 443-450
• 4 Gu W, Lloyd DJ, Chinookswong N. et al. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice. J Pharmacol Exp Ther 2011; 338: 70-81
• 5 Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142: 521-527
• 6 Day JW, Ottaway N, Patterson JT. et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009; 5: 749-757
• 7 Cohen MA, Ellis SM, Le Roux CW. et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88: 4696-4701
• 8 Ding X, Saxena NK, Lin S. et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173-181
• 9 Parlevliet ET, Wang Y, Geerling JJ. et al. GLP-1 Receptor activation inhibits vldl production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-leiden mice. PLoS One 2012; 7: e49152
• 10 Caren R, Corbo L. Glucagon and cholesterol metabolism. Metabolism 1960; 9: 938-945
• 11 Habegger KM, Heppner KM, Geary N. et al. The metabolic actions of glucagon revisited. Nat Rev Endocrinol 2001; 6: 689-697
• 12 Patel V, Joharapurkar AA, Kshirsagar SG. et al. Central GLP-1 receptor activation improves cholesterol metabolism partially independent of its effect on food intake. Can J Physiol Pharmacol. 2016; 94: 161-167
• 13 Patel V, Joharapurkar A, Kshirsagar S. et al. Central and peripheral glucagon reduces hyperlipidemia in rats and hamsters. Drug Res (Stuttg) 2017; 67: 318-326
• 14 Patel V, Joharapurkar A, Dhanesha N. et al. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice. Can J Physiol Pharmacol 2013; 91: 1009-1015
• 15 Green BD, Mooney MH, Gault VA. et al. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). Metabolism 2004; 53: 252-259
• 16 Unson CG, Andreu D, Gurzenda EM. et al. Synthetic peptide antagonists of glucagon. Proceedings of the National Academy of Sciences 1987; 84: 4083-4087
• 17 Micanovic R, Raches DW, Dunbar JD. et al. Different roles of N-and C-termini in the functional activity of FGF21. Journal of Cellular Physiology 2009; 219: 227-234
• 18 Dallas-Yang Q, Shen X, Strowski M. et al. Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. Eur J Pharmacol 2004; 501: 225-334
• 19 Adams AC, Coskun T, Rovira AR. et al. Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 2012; 7: e38438
• 20 Patel V, Joharapurkar A, Dhanesha N. et al. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice. Pharmacol Rep 2013; 65: 927-936
• 21 Johansson SM, Yang JN, Lindgren E. et al. Eliminating the antilipolytic adenosine A1 receptor does not lead to compensatory changes in the antilipolytic actions of PGE2 and nicotinic acid. Acta Physiol (Oxf) 2007; 190: 87-96
• 22 Pocai A, Carrington PE, Adams JR. et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009; 58: 2258-2266
• 23 Quinones M, Al-Massadi O, Gallego R. et al. Hypothalamic CaMKKbeta mediates glucagon anorectic effect and its diet-induced resistance. Mol Metab 2015; 4: 961-970
• 24 Perea A, Clemente F, Martinell J. et al. Physiological effect of glucagon in human isolated adipocytes. Horm Metab Res 1995; 27: 372-375
• 25 Villanueva-Penacarrillo ML, Marquez L, Gonzalez N. et al. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 2001; 33: 73-77
• 26 Guzman CB, Zhang XM, Liu R et al. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2017 [Epub ahead of print]
• 27 Parlevliet ET, Schroder-van der Elst JP, Corssmit EP. et al. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice. J Pharmacol Exp Ther 2009; 328: 240-248
• 28 Habegger KM, Stemmer K, Cheng C. et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 2013; 62: 1453-1463
• 29 Samson SL, Sathyanarayana P, Jogi M. et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 2011; 54: 3093-3100
• 30 Badman MK, Pissios P, Kennedy AR. et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5: 426-437
• 31 Fisher FM, Chui PC, Antonellis PJ. et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781-2789
• 32 Hale C, Chen MM, Stanislaus S. et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 2012; 153: 69-80
• 33 Cyphert HA, Ge X, Kohan AB. et al. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J Biol Chem 2012; 287: 25123-25138